1. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
- Author
-
Zhuang, Wei, Xie, Jing‐Dun, Zhou, Shan, Zhou, Zhi‐Wei, Zhou, Yi, Sun, Xiao‐Wei, Yuan, Xiu‐Hong, Huang, Min, Liu, Si, Xin, Shuang, Su, Qi‐Biao, Qiu, Hai‐Bo, and Wang, Xue‐Ding
- Subjects
- *
IMATINIB , *GASTROINTESTINAL stromal tumors , *TREATMENT of chronic myeloid leukemia , *DRUG side effects , *THERAPEUTICS , *TUMOR treatment - Abstract
Abstract: Imatinib at 400 mg daily is the standard treatment for patients affected with CML and GIST. The intervariability in plasma concentration is very significant. In many reports, a good therapeutic effect is attributed to an adequate concentration of Imatinib. However, few studies have been conducted to investigate the association between plasma concentration and side effects. Besides, no upper concentration limit of Imatinib plasma concentration detection has been established. The correlation of Imatinib trough concentrations (Cmin) with adverse effects (AEs) was described here. Plasma samples were obtained from patients after 3 months treatment with Imatinib (steady state,
n = 122). Liquid chromatography/ tandem mass spectrometry was used to determine the concentration of Imatinib and its metabolite NDI. The incidence of myelosuppression was increased significantly with the increased Imatinib trough plasma concentration. The plasma level of Imatinib and NDI in patients who developed myelosuppression are 1698.3 ± 598.6 ng/mL and 242.1 ng/mL, respectively, which were significantly higher than those in patients who did not (1327.2 ± 623.4 ng/mL,P =P =- Published
- 2018
- Full Text
- View/download PDF